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Background: Overweight contributes to type 2 diabetes mellitus (T2DM) development.
Although the obesity paradox has been suggested in many vascular diseases, little
information is available about stroke patients with T2DM. We investigated whether
body mass index (BMI) has a differential impact on the incidence of major adverse
cardiovascular events (MACE) in patients with ischemic stroke and T2DM.
Methods: This retrospective study used a prospective cohort of patients with acute
ischemic stroke and included consecutive patients with T2DM after excluding those
with active cancer or who died within 1 month of an index stroke. We investigated
the long-term risk of MACE (stroke, myocardial infarction, unstable angina, coronary
revascularization procedure, and death) according to BMI.
Results: Among the 1,338 patients, MACE occurred in 415 patients (31.1%) during
a median follow-up of 3.6 years. Compared to the normal weight group, MACE
occurred more frequently in the underweight group [adjusted hazard ratio (HR) 1.55,
95% confidence interval (CI): 1.01–2.38], but less frequently in the overweight group
(adjusted HR: 0.87, 95% CI: 0.70–1.08) and obese group (adjusted HR: 0.58, 95%
CI: 0.41–0.86) group. In analyses of association between BMI and each component
of MACE, stroke and cardiovascular mortality indicated an L- and a U-shaped pattern,
respectively. However, fatal or non-fatal stroke showed an inverse pattern, and fatal or
non-fatal cardiovascular events showed a reversed J-shaped pattern.
Discussions: This study showed the overall presence of the obesity paradox in stroke
patients with T2DM. However, obese patients had different risks of cardiovascular events
and stroke.
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INTRODUCTION
Obesity and diabetes mellitus are established risk factors for vascular disease (1). However, leaner
adults have higher mortality rates than obese or overweight adults (2–4). This phenomenon has
been called the obesity paradox and has been implicated in vascular diseases, including stroke and
cardiovascular disease (CVD), as well as chronic diseases, such as hypertension, end stage renal
disease, chronic obstructive pulmonary disease, and peripheral artery disease (5–9).
Park et al. Obesity Paradox in Stroke With DM
Many patients with type 2 diabetes mellitus (T2DM) are
overweight or obese. Overweight is associated with impaired
glucose tolerance and insulin resistance, which contribute to
the development of T2DM. Due to the pathophysiological
relationship between overweight and T2DM, several studies have
investigated the association between body mass index (BMI)
and mortality in patients with T2DM. Meta-analyses and large
cohort studies in patients with T2DM alone showed a U-shaped
or J-shaped relationship between BMI and long-term mortality
(10–16). In contrast to these T2DM patients, BMI was inversely
correlated with mortality in patients with T2DM and acute
heart failure (HF) (17). In a prospective cohort study of T2DM
patients without known CVD at baseline, overweight or obese
patients had a higher rate of cardiac events, such as acute
coronary syndrome and HF than those with normal BMI. In
the same population, however, the risk of mortality was lower
in overweight patients than those with normal BMI (12). These
findings suggest that the relationship of BMI with the adverse
effects of T2DM may differ depending on the specific disease
group. In this study, we investigated whether the incidence of
major adverse cardiovascular events (MACE) differs according to
BMI in patients with ischemic stroke and T2DM.
MATERIALS AND METHODS
Study Population
This was a retrospective, observational study of prospectively
registered patients with ischemic stroke and T2DM included in
the Yonsei Stroke Cohort (18). Within 7 days of symptom onset,
the cohort enrolled consecutive patients with acute ischemic
stroke that have been admitted to the Severance Stroke Center of
FIGURE 1 | Flow chart of patient selection.
Yonsei University in South Korea. All patients underwent brain
magnetic resonance imaging and/or computerized tomography
and cerebral angiography (magnetic resonance angiography,
computerized tomography angiography, or digital subtraction
angiography). Routine evaluations of patients included standard
blood tests, 12-lead electrocardiography, chest radiography,
echocardiography, and continuous electrocardiographic
monitoring while in the stroke unit or being Holter monitored.
Glycated hemoglobin level was routinely assessed in patients
with fasting blood sugar ≥ 5.55 mmol/L. All patients were
managed according to a standardized protocol and care pathway,
which were based on the guidelines.
T2DM was defined based on the American Diabetes
Association criteria (19), which include a history of T2DM,
current use of hypoglycemic medications or insulin, glycated
hemoglobin ≥6.5%, fasting blood glucose level ≥7 mmol/L, or
random blood glucose level ≥11.1 mmol/L with typical diabetic
symptoms, and no signs of type 1 diabetes. This study was
approved by the Institutional Review Board of Yonsei University
Health System with a waiver of patients’ informed consent due to
the retrospective nature of the study.
Clinical Variables
We collected data for demographics, vascular risk factors for
and previous history of stroke, coronary artery occlusive disease,
peripheral artery occlusive disease, and chronic kidney disease.
Hypertension was defined as systolic blood pressure ≥140
mmHg, diastolic blood pressure ≥90 mmHg, or any history
of anti-hypertensive agents. Hyperlipidemia was defined as
serum total cholesterol ≥6.21 mmol/L, low-density lipoprotein
cholesterol ≥4.14 mmol/L, or history of using lipid-lowering
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FIGURE 2 | Kaplan–Meier survival analysis for major adverse cardiovascular event (MACE) according to body mass index in patients with ischemic stroke and type 2
diabetes mellitus.
drugs after the diagnosis of hyperlipidemia. Current smoking
was defined as a history of smoking any cigarettes within
1 year before admission. We also obtained a history of
previously used medication at admission, which included
anticoagulants, anti-platelet agents, anti-hypertensive agents,
and statins. Laboratory data were also obtained for complete
blood counts, lipid profile, initial blood glucose, glycated
hemoglobin, blood urea nitrogen, and creatinine. The severity
of stroke was assessed using the National Institutes of Health
Stroke Scale (NIHSS) at admission. BMI at admission was
calculated as weight in kilograms divided by height in meters
squared (kg/m2).
Follow-Up and Outcomes
After discharge, we regularly followed up patients at 3 months,
1 year, and every year thereafter. At each follow-up visit,
we collected medical data on any cases of cardiovascular
events or mortality via face-to-face interviews with neurologists
or clinical research associates in an outpatient clinic. When
the patients missed the visit, we obtained the information
from the patient or their families via telephone interviews
based on a structured questionnaire (20). We obtained
necessary data by reviewing the medical records, if available.
In addition, we also obtained mortality data from the
Korean National Statistical Office (http://www.kostat.go.kr)
using death certificates.
The primary outcome was the composite rate of MACE,
which include non-fatal or fatal stroke, non-fatal or fatal
myocardial infarction (MI), unstable angina, coronary
revascularization procedure, and any death. Cardiovascular
mortality was defined as any mortality due to MI, other
cardiac diseases, or sudden death. Censoring date was
December 31, 2013.
Statistical Analysis
The patients were categorized into four groups according to
BMI for the Asian population (underweight: BMI < 18.5 kg/m2;
normal weight: 18.5 kg/m2 ≤ BMI < 23 kg/m2; overweight:
23 kg/m2 ≤ BMI < 27.5 kg/m2; and obese: BMI ≥ 27.5
kg/m2) provided by the World Health Organization Expert
Consultation panel for appropriate BMI (21). The data were
presented as mean ± standard deviation, median (interquartile
range), or as number (%), as appropriate. The Shapiro–Wilk
test was done to test normality of the continuous variables.
The differences between the groups were compared using
Kruskal–Wallis test for the continuous variable and a chi-
square test or Fisher’s exact test for the categorical variable.
Post-hoc analyses were used for assessing the magnitude of
the differences.
The survival curves were determined and plotted using the
Kaplan–Meier method, and the group differences in survival
time were analyzed using a log-rank test. To determine the
independent predictor for MACE, the Cox proportional hazards
regression analysis was used and summarized as hazard ratio
(HR) and 95% confidential interval (CI). For multivariate
analysis, age, sex, initial NIHSS, and variables with p < 0.1 in the
univariate analyses were entered as covariates. The continuous
measure of BMI was used to fit a smooth spline curve to obtain
a representation of log HR for each component of MACE and
mortality by adjusting the variables that were entered into the
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TABLE 1 | Clinical characteristics of patients according to BMI categories.
Underweight (N = 40) Normal weight (N = 421) Overweight (N = 698) Obese (N = 179) p
DEMOGRAPHICS
Age, years 71.0 ± 10.0 68.6 ± 10.9 65.7 ± 10.6 64.6 ± 11.0 0.000b,c,d,e
Sex, male 26 (65.0) 244 (58.0) 461 (66.0) 82 (45.8) 0.000c,d,e
Systolic blood pressures, mmHg 155.8 ± 31.0 156.4 ± 29.5 156.1 ± 29.4 160.9 ± 31.0 0.261
Diastolic blood pressures, mmHg 78.5 ± 16.6 84.2 ± 17.2 85.2 ± 15.8 87.7 ± 15.0 0.006a,b,c,e
Body mass index, kg/m2 17.1 ± 1.3 21.3 ± 1.2 24.8 ± 1.2 30.0 ± 3.2 0.000a,b,c,d,e,f
Initial NIHSS score 2 [5–10] 2 [4–8] 1 [3–6] 2 [3–6] 0.036b,d
RISK FACTORS
Hypertension 29 (72.5) 334 (79.3) 576 (82.5) 160 (89.4) 0.010c,d,f
Smoking 6 (15.0) 78 (18.5) 186 (26.6) 27 (15.1) 0.055d,f
Hyperlipidemia 7 (17.5) 87 (20.7) 176 (25.2) 51 (28.5) 0.110 e
PAOD 4 (10.0) 36 (8.6) 41 (5.9) 11 (6.1) 0.296
CAOD 11 (27.5) 120 (28.5) 202 (28.9) 45 (25.1) 0.791
Previous stroke 8 (20.0) 65 (15.4) 108 (15.5) 21 (11.7) 0.485
Atrial fibrillation 10 (25.0) 80 (19.0) 145 (20.8) 29 (16.2) 0.435
Chronic kidney disease 8 (20.0) 74 (17.6) 78 (11.2) 19 (10.6) 0.007d,e
LABORATORY FINDINGS
Hemoglobin, g/L 12.8 ± 2.1 13.4 ± 2.0 14.0 ± 2.1 14.0 ± 1.9 0.000b,c,d,e
White blood cells, 109/L 8,684.8 ± 2,975.0 8,526.5 ± 3,074.7 8,668.3 ± 3,214.7 8,944.8 ± 3,078.8 0.363
Platelets, 109/L 249.2 ± 79.8 255.7 ± 82.9 249.1 ± 75.2 261.8 ± 81.6 0.126
Blood urea nitrogen, mmol/L 23.4 ± 16.3 19.9 ± 11.9 17.9 ± 9.1 19.4 ± 13.8 0.042b,c,d
Creatinine, µmol/L 1.5 ± 1.6 1.3 ± 1.3 1.2 ± 1.2 1.1 ± 1.1 0.326
Total cholesterol, mmol/L 167.6 ± 35.1 177.7 ± 45.7 181.4 ± 46.6 189.1 ± 55.7 0.025c,e
Triglyceride, mmol/L 89.0 ± 38.8 128.9 ± 78.6 147.1 ± 100.0 151.1 ± 84.0 0.000a,b,c,d,e
HDL-cholesterol, mmol/L 43.1 ± 13.5 40.9 ± 10.6 40.2 ± 10.5 39.6 ± 9.8 0.224
LDL-cholesterol, mmol/L 106.5 ± 32.0 111.1 ± 40.7 111.9 ± 39.8 118.8 ± 43.4 0.155e,f
Glycated hemoglobin 7.2 ± 1.4 7.6 ± 1.7 7.6 ± 1.5 7.7 ± 1.5 0.316
Glucose, mmol/L 191.4 ± 80.9 184.3 ± 85.9 189.4 ± 79.7 181.1 ± 74.1 0.356c,e
PREMORBID MEDICATION
Antiplatelet agents 17 (42.5) 166 (39.4) 265 (38.0) 66 (36.9) 0.872
Anticoagulants 2 (5.0) 26 (6.2) 37 (5.3) 9 (5.0) 0.916
Statins 9 (22.5) 84 (20.0) 163 (23.4) 41 (22.9) 0.610
Antihypertensive agents 12 (30.0) 142 (33.7) 261 (37.4) 74 (41.3) 0.244
Data are shown as n (%), mean ± standard deviation, or median [interquartile range]. NIHSS, National Institutes of Health Stroke Scale; PAOD, peripheral artery occlusive disease;
CAOD, coronary artery occlusive disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
aNormal weight vs. Underweight, p < 0.05.
bNormal weight vs. Overweight, p < 0.05.
cNormal weight vs. Obese, p < 0.05.
dUnderweight vs. Overweight, p < 0.05.
eUnderweight vs. Obese, p < 0.05.
fOverweight vs. Obese, p < 0.05.
multivariate analysis. All tests were two-sided and p < 0.05 was
considered as statistically significant. R software, 3.3.2 version (R
foundation for Statistical Computing, Vienna, Austria) was used
for statistical analyses.
RESULTS
Characteristics of Patients
Between January 2007 and July 2013, a total of 3,727 consecutive
patients with ischemic stroke were registered. After excluding
2,296 patients without T2DM, we excluded further 59 patients
with active cancer (diagnosed or receiving antimitotic treatment
within the past 6 months, recurrent, metastatic, or inoperable)
(22). Then, we excluded 34 patients who died within 1 month
from index stroke because their deaths may have been directly
related to the index stroke. Finally, a total of 1,338 patients were
included for this study (Figure 1).
The mean age of the patients was 66.6 ± 10.9 years, and 813
were men (60.8%). There were 40 (2.9%) underweight patients,
421 patients (31.5%) with normal weight, 698 overweight patients
(52.2%), and 179 obese patients (13.4%). Several variables were
different between groups, including age, sex, diastolic blood
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TABLE 2 | Unadjusted and adjusted hazard ratio for MACE of type 2 diabetes
patients with acute ischemic stroke according to BMI.
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
DEMOGRAPHICS
Age, years 1.06 (1.05–1.07) 0.000 1.04 (1.03–1.05) 0.000
Sex, male 0.84 (0.69–0.92) 0.066 1.15 (0.92–1.45) 0.229
Initial NIHSS score 1.10 (1.08–1.11) 0.000 1.1 (1.09–1.11) 0.000
RISK FACTORS
Hypertension 1.31 (0.99–1.72) 0.052
Smoking 0.73 (0.56–0.93) 0.010 1.22 (0.91–1.63) 0.190
Hyperlipidemia 0.77 (0.60–0.99) 0.032 0.87 (0.65–1.16) 0.333
PAOD 1.64 (1.18–2.27) 0.005 1.15 (0.80–1.63) 0.451
CAOD 1.03 (0.84–1.28) 0.759
Previous stroke 1.21 (0.95–1.56) 0.138
Atrial fibrillation 1.87 (1.52–2.32) 0.000 0.97 (0.76–1.23) 0.777
Chronic kidney
disease
2.05 (1.62–2.58) 0.000 1.32 (0.96–1.82) 0.088
LABORATORY FINDINGS
Hemoglobin 0.82 (0.78–0.85) 0.000 0.88 (0.84–0.93) 0.000
White blood cells 1.00 (1.00–1.00) 0.007
Platelets 0.99 (0.99–1.00) 0.052
Blood urea
nitrogen
1.23 (1.02–1.03) 0.000 1.01 (0.99–1.02) 0.146
Creatinine 1.14 (1.08–1.20) 0.000 1.03 (0.94–1.13) 0.273
Total cholesterol 1.00 (0.99–1.00) 0.000 0.98 (0.95–1.02) 0.368
Triglyceride 1.00 (0.99–1.00) 0.000 1.00 (0.99–1.01) 0.515
HDL-cholesterol 0.99 (0.98–1.00) 0.000 1.01 (0.97–1.05) 0.584
LDL-cholesterol 0.99 (0.99–1.00) 0.000 1.02 (0.98–1.06) 0.348
Glycated
hemoglobin
0.92 (0.99–0.99) 0.011 1.01 (0.95–1.08) 0.762
PREMORBID MEDICATION
Antiplatelet agents 1.07 (0.88–1.30) 0.503
Anticoagulants 1.14 (0.77–1.70) 0.517
Statins 1.10 (0.88–1.38) 0.419
Antihypertensive
agents
1.25 (1.02–1.54) 0.035 1.03 (0.83–1.27) 0.753
BODY MASS INDEX 0.000 0.001
Underweight 2.02 (1.34–3.07) 0.001 1.55 (1.01–2.38) 0.046
Normal weight Reference Reference
Overweight 0.70 (0.56–0.86) 0.001 0.87 (0.70–1.08) 0.111
Obese 0.45 (0.31–0.65) 0.000 0.58 (0.41–0.86) 0.001
HR, hazard ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale;
PAOD, peripheral artery occlusive disease; CAOD, coronary artery occlusive disease;
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
pressures, initial NIHSS, hemoglobin, blood urea nitrogen, total
cholesterol, triglyceride, a history of hypertension, smoking, and
chronic kidney disease (Table 1).
Outcomes
During the mean follow-up for 3.6 ± 1.8 years, MACE occurred
in 415 patients (31.1%). All-cause death occurred in 351 [26.2%,
fatal stroke in 100 (7.5%), fatal MI in 28 (2.1%), and other fatal
events in 223 (16.7%)]. Mean annual event rates for MACE were
39.2% in the underweight, 18.0% in the normal weight, 12.0% in
the overweight, and 7.5% in the obese group.
Kaplan–Meier curve analysis showed that MACE occurred
more frequently in the normal weight group than the overweight
or the obese group, but less frequently than the underweight
group (log rank, p < 0.001) (Figure 2). After adjustment for
age, sex, initial NIHSS, and variables with p < 0.10 in the
univariate analysis, the obese group showed a significantly lower
risk for MACE than the normal weight group (adjusted HR:
0.58, 95% CI: 0.41–0.86, p < 0.05) (Table 2). The risk for MACE
was significantly higher in the underweight group than the
normal weight group (adjusted HR: 1.55, 95% CI: 1.01–2.38,
p < 0.05) (Table 2).
We determined the association of BMI with the risk for
each component of MACE and mortality using the spline curve
of log HR according to BMI as a continuous variable. While
the all-cause mortality and cardiovascular mortality showed
a U-shaped or a reversed J-shaped pattern, stroke mortality
showed an L-shaped pattern. Other-cause mortality (death due
to conditions other than CVD or stroke) showed an inverse
relationship with BMI (Figure 3). A stroke (fatal or non-fatal
stroke) showed a pattern of inverse relationship with BMI.
However, any cardiovascular event (fatal or non-fatal event)
showed a reversed J-shaped pattern in that the slope of the curve
was sharply increased in body weight range belonging to the
obese group (Figure 4).
DISCUSSION
This study showed an inverse relationship between BMI
and occurrence of MACE in patients with acute stroke and
T2DM. However, the risk for each component of MACE
differed according to the BMI. While BMI had an inverse
association with other-cause mortality, it had an L-shaped
association with stroke mortality, and a U-shaped association
with cardiovascular mortality.
Most studies in patients with T2DM alone showed the U-
shaped association of BMI with all-cause and cardiovascular
mortality (10, 11, 13, 14, 23). However, studies in T2DM patients
with comorbidity suggested heterogeneity in mortality according
to the specific comorbidity. The J-shaped pattern of mortality was
observed in T2DM patients who were free of CVD and cancer
(16). In patients with acute MI and T2DM, there were no survival
advantages from an elevated BMI (24).While there was U-shaped
association in patients with chronic HF and T2DM, there was an
inverse association in those with acute HF and T2DM (17). This
study also showed that the risk of cardiovascular mortality was
higher in obese patients than in overweight patients. However,
stroke mortality was not higher in obese patients, which supports
the heterogeneity of mortality in T2DM patients according to
the comorbidity.
While a majority of previous studies on the obesity paradox
have focused on mortality, overweight or obesity may be a risk
for vascular events. Therefore, we investigated the occurrence
of non-fatal stroke and cardiovascular events as well as fatal
events. This analysis showed that the risk for any stroke (fatal
or non-fatal) in obese patients decreased and showed an inverse
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FIGURE 3 | Relative hazards of body mass index (BMI) on (A) all-cause mortality; (B) fatal stroke; (C) fatal cardiovascular events; and (D) other-cause mortality after
adjusting variables p < 0.1 in the univariate Cox regression analysis.
association with BMI. However, the risk of any cardiovascular
events (fatal or non-fatal) sharply increased in obese patients
and showed a reversed J-shaped pattern. These findings suggest
that the risk of stroke and cardiovascular events is different
in stroke patients with T2DM and obesity, in that the risk
of cardiovascular events may increase and that the risk of
stroke may not increase. The reason for the discrepancy in
stroke incidences and cardiovascular events in obese patients is
uncertain. However, while obesity is a common risk factor for
both cardiovascular events and stroke, the attributable risk of
obesity is higher for cardiovascular events than stroke (25).
In contrast to obese patients, underweight patients with
T2DM and stroke consistently showed poor outcomes in
this study. Previous studies also showed poor outcomes in
underweight T2DM patients. The patients who have a greater
genetic susceptibility to T2DM have a greater chance of
developing T2DM at lower BMI, which will consequently lead to
a poor prognosis (12). In a study that assessed weight loss after
stroke, weight loss > 3 kg was associated with poor outcomes
after stroke (26). Muscle power is crucial for mobilization and
effective rehabilitation after stroke. Immobilization is associated
with various complications and poor outcomes (27, 28). Lean
muscle mass in underweight patients might negatively impact
their mobility, which could contribute to poor outcome.
This study in stroke patients with T2DM yielded the best
outcomes in terms of mortality and MACE in the overweight.
However, it remains uncertain whether an intervention for
body weight modification should be targeted to remain
overweight because our findings and others’ are based on
observational studies. Current guidelines for the secondary
prevention of ischemic stroke recommend weight loss and
aerobic exercise (29, 30). Strength training is also beneficial in
patients with T2DM as it increases glucose uptake and insulin
signaling in skeletal muscles (31). Thus, instead of a uniform
weight loss recommendation for ischemic stroke patients with
T2DM, an individualized approach depending on weight status
may be needed.
There are limitations in our study. First, this study
is a retrospective, single-center study in the single ethnic
population, which limits the generalization of findings. Second,
we simply categorized the patients according to BMI at
admission, which does not reflect changes in body weight
over time. In addition, this study did not assess the muscle
mass, which may be an important factor for prognosis.
Third, while it is known that each category of diabetic
drug may affect body weight (32), information about diabetic
medications before admission was not collected. Lastly, this
study may be subjected to the selection bias because a
significant portion of screened patients excluded according to the
inclusion criteria.
CONCLUSIONS
This study showed the overall presence of the obesity paradox
in stroke patients with T2DM. However, obese patients had
different risks of cardiovascular events and stroke. Since the
risk of cardiovascular events sharply increased in obese patients,
Frontiers in Neurology | www.frontiersin.org 6 June 2019 | Volume 10 | Article 563
Park et al. Obesity Paradox in Stroke With DM
FIGURE 4 | Relative hazards of BMI on (A) major adverse cardiovascular events; (B) any stroke events; (C) any cardiovascular events after adjusting variables p < 0.1
in the univariate Cox regression analysis.
we may have to be more attentive to these patients to prevent
these events. This could be done by assessing for asymptomatic
coronary artery disease, considering that approximately one-
third of stroke patients have asymptomatic significant (≥50%)
coronary artery disease, and these patients have poor long-term
outcomes (20, 33).
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